Evidence map›Paper›PMID 42213490›Full record

ArticleCancer reports (Hoboken, N.J.)2026

Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A.

Xinmiao Xiong, Chuanfang Shu, Ziqun Qu, Jiayan Li, Wei Ye, Lili Wang

Abstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinmiao XiongDepartment of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.ORCID 0000-0002-5704-6646
Chuanfang ShuDepartment of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.ORCID 0009-0004-0506-8810
Ziqun QuDepartment of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.ORCID 0009-0006-3126-131X
Jiayan LiThe Clinical Infectious Disease Center of Nanjing, Nanjing, Jiangsu, China.ORCID 0009-0003-9464-8501
Wei YeDepartment of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.ORCID 0000-0002-0513-4142
Lili WangThe Clinical Infectious Disease Center of Nanjing, Nanjing, Jiangsu, China.ORCID 0000-0001-9800-5130

Funding

Jiangsu Commission of Health H2023092Jiangsu provincial Cadre Health Care Research Project BJ25045Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau YKK22132Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau YKK24179The Clinical Infectious Disease Center of Nanjing CXZX202232The Second Hospital of Nanjing HBRCYL06The Second Hospital of Nanjing RCZD230004
6 · The paper itself

Abstract

backgroundN

aimsThis study aimed to elucidate the regulatory axis between METTL14 and VEGFA in HCC. Specifically, we sought to determine whether METTL14 functions as a suppressor of HCC progression by restricting VEGFA-driven angiogenesis through an m

methodsQuantitative m

resultsm

conclusionMETTL14 functions as a critical tumor suppressor in HCC by restricting VEGFA-driven angiogenesis via m

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMethyltransferasesNeovascularization, PathologicVascular Endothelial Growth Factor AAnimalsCell Line, TumorCell ProliferationEpitranscriptomeFemaleGene Expression Regulation, NeoplasticHumansMaleMiceRNA MethylationMethyltransferasesMETTL14 protein, humanVascular Endothelial Growth Factor AVEGFA protein, humanangiogenesishepatocellular carcinomaMETTL14post‐transcriptional modificationVEGFA

Identifiers

PMID42213490
PMCPMC13239874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.